These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 39081326)

  • 1. Trained immunity inducers in cancer immunotherapy.
    Sui Y; Berzofsky JA
    Front Immunol; 2024; 15():1427443. PubMed ID: 39081326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
    Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of trained immunity.
    Mulder WJM; Ochando J; Joosten LAB; Fayad ZA; Netea MG
    Nat Rev Drug Discov; 2019 Jul; 18(7):553-566. PubMed ID: 30967658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
    Galati D; Zanotta S
    Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effects of Trained Innate Immunity on T Cell Responses; Clinical Implications and Knowledge Gaps for Future Research.
    Murphy DM; Mills KHG; Basdeo SA
    Front Immunol; 2021; 12():706583. PubMed ID: 34489958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines.
    Bullock TNJ
    Clin Transl Sci; 2021 Jan; 14(1):120-131. PubMed ID: 32770735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trained immunity: Target for prophylaxis and therapy.
    Ziogas A; Bruno M; van der Meel R; Mulder WJM; Netea MG
    Cell Host Microbe; 2023 Nov; 31(11):1776-1791. PubMed ID: 37944491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
    Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
    Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoural immunotherapies in oncology.
    Xu W; Atkinson VG; Menzies AM
    Eur J Cancer; 2020 Mar; 127():1-11. PubMed ID: 31962197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Local Radiation Therapy in Cancer Immunotherapy.
    Demaria S; Golden EB; Formenti SC
    JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
    Zhang M; Kim JA; Huang AY
    Front Immunol; 2018; 9():341. PubMed ID: 29535722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the development of cancer immunotherapies.
    Gao J; Bernatchez C; Sharma P; Radvanyi LG; Hwu P
    Trends Immunol; 2013 Feb; 34(2):90-8. PubMed ID: 23031830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
    Fecek RJ; Storkus WJ
    Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Turning tumors into vaccines: co-opting the innate immune system.
    van den Boorn JG; Hartmann G
    Immunity; 2013 Jul; 39(1):27-37. PubMed ID: 23890061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.